You mainly live in London and the southeast - two thirds of you to be exact, with 58 per cent from
London. That means PosNation's geographical reach pretty much reflects
the HIV positive population.
What are you on?
Seven out of 10 HIV positive PosNation readers take anti-HIV medication,
though a surprisingly high one in 10 have taken it in the past but currently
do not. Women are just as likely to take treatments as men, but white
women somewhat less so.
Which drugs you take have changed quite a bit since 1999. Over three-quarters
of you take 3TC in some form, making it by some way the most widely-prescribed
drug, and nearly half take AZT -mainly in the combo formulations Combivir
and Trizivir. d4T has fallen from no. 1 to no. 5 in the 'hit parade',
and ddI from no 3 to no 8. The non-
page 5 of 9
1
/ 2
/ 3
/ 4
/ 5 / 6
/
7
/ 8
/ 9
contents
of issue 80/81
back
issues
the
gazette
recipes
small
ads
contacting
us
weblinks
"Strikes a good balance between serious reporting, reflecting, and the more enloyable, lighter aspects of living"
nucleosides nevirapine and efavirenz are now more popular than the protease
inhibitors (PIs). If you take ritonavir away from the PIs (because it
is nearly always used as a 'booster' these days and not in its own right),
it appears that only one in eight are taking a PI as an active ingredient
in their combo therapy.
Only a third as many people take either nelfinavir or indinavir as did
in 1999. Already more take the new drug tenofovir than indinavir. Doctor
and patient decisions seem to be being guided partly by actual or reputed
toxicity, but more especially by ease of adherence.
Do we speak the right language?
You trust us. Ninety-six per cent of you agreed: "I think what I read in Positive
